Products

At BSIM Therapeutics we are developing the next generation of therapies tailored to treat transthyretin-mediated amyloidoses and their associated co-morbidities.

ATTR - EYE

Endowed with specific molecular properties, some of our potent transthyretin stabilizers have been crafted to reach the inner compartments of the eye and thus prevent vitreous opacities, conjunctival microaneurysms, dry eye and glaucoma.

ATTR - BRAIN

Some of our most potent transthyretin stabilizers have been designed to enable their crossing of the blood brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). Thus, they may prevent both CNS and PNS manifestations in ATTR in the long term.

hATTR - PNS

Our most potent transthyretin stabilizers display optimal balance between potency, selectivity for TTR and safety in long-term treatments. They were designed in ways that enable them to reach the blood plasma, thus stalling the progression of PNS symptoms in hATTR-PN, and additionally to reach the CNS to prevent CNS-associated symptoms.

hATTR - HEART

Because some of our most potent transthyretin stabilizers are also resilient to the effect of mutations in TTR, they may be used in the treatment of cardiomyopathies mediated by different TTR forms, such as TTR V122I and wild-type TTR, that deposit as amyloid fibrils in the heart.

wtATTR - HEART

Because some of our most potent transthyretin stabilizers are also resilient to the effect of mutations in TTR, they may be used in the treatment of cardiomyopathies mediated by different TTR forms, such as TTR V122I and wild-type TTR, that deposit as amyloid fibrils in the heart.

Program

Discovery

Optimization

Preclinical

Phase I/ II

Program

D

O

PC

C

ATTR EYE

ATTR CNS

hATTR-PN

hATTR-CM

wtATTR HEART

D - Discovery

O - Optimization

PC - Preclinical

C - Clinical (Phase I/II)

By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more